Viracor-IBT Laboratories explained

Viracor Eurofins Laboratories is a diagnostic laboratory specializing in infectious disease, immunology and allergy testing for immunocompromised and critical patients. Viracor Eurofins works with medical professionals, transplant teams, reference labs and bio-pharmaceutical companies.

Viracor-IBT has CLIA clinical laboratory certification as both an Infectious Disease Laboratory and as an Allergy & Immunology Laboratory.[1]

History

Viracor-IBT was created through the merger of two specialty diagnostic testing labs, Viracor Laboratories and IBT Laboratories.[2] Founded by Dr. Konstance Knox and Dr. Donald Carrigan in Milwaukee County in 2000, Viracor was among the first to commercially offer real-time quantitative PCR assays to diagnose patients with Adenovirus, BK virus and JC virus, among others. Founded in 1983, IBT was the first laboratory to offer a test to definitively diagnose autoimmune causes of chronic hives and developed the first commercially available test to measure pneumococcal antibodies.

On 1 July 2014, Ampersand Capital Partners completed the sale of Viracor-IBT Laboratories to Eurofins Scientific for $255 million. The company continued to be known as Viracor-IBT.[3]

Expertise

The core areas of expertise for Viracor-IBT are:[4]

External links

Notes and References

  1. Web site: Licenses & Certifications. Viracor-IBT Laboratories, Inc.. 8 November 2017.
  2. ViraCor, IBT Laboratories merge. Kansas City Business Journal. 30 June 2009. 8 November 2017.
  3. Web site: Ampersand Capital Partners. Ampersand Sells Viracor-IBT To Eurofins For $255 Million. PR Newswire. 8 November 2017.
  4. Web site: Areas of Expertise. Viracor-IBT Laboratories, Inc.. 8 November 2017.